KardiAssure

KardiAssure - Insight is at hand

Convenient, accurate, objective evaluation of Medication Adherence is a critical missing piece in achieving better control of cardiovascular disease (CVD) and its associated risk factors and complications.

Are your patients adhering to their cardiovascular (CV) medication prescription regimen?

It's hard to know, unless you use KardiAssure, the first and only adherence test for CV medications.

KardiAssure provides you with clear, reliable, actionable information on your patients' CV medication adherence, helping you provide the best possible care.

Cardiovascular Disease is the Leading Cause of Death in the U.S.

  • Hypertension affects 1 in 3 adults in the United States

    Hypertension affects 1 in 3 adults in the United States

    Source: Merai R, Siegel C, Rakotz M, et al. CDC Grand Rounds: A Public Health Approach to Detect and Control Hypertension. MMWR Morb Mortal Wkly Rep. 2016 Nov 18;65(45):1261-1264.

  • Hypertension accounts for $46 billion in U.S. spend

    Hypertension accounts for $46 billion in U.S. spend

    Source: Mozzafarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2015 Update: a report from the American Heart Association. Circulation. 2015;e29-322.

  • 50% of hypertensive patients are non-adherent to their cardiovascular medications

    50% of hypertensive patients are non-adherent to their cardiovascular medications

    Source: Abegaz MA, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Jan; 96(4): e5641.

  • 125,000 preventable deaths per year related to nonadherence

    125,000 preventable deaths per year related to nonadherence

    Source: http://bemedicinesmart.org. National Council on Patient Information and Education. Accelerating Progress in Prescription Medicine Adherence: The Adherence Action Agenda. A National Action Plan to Address America’s “Other Drug Problem.” Updated: October 2013. Viewed: January 5, 2018.

Current Approaches Have Limitations

Challenges chart

Our Solution

Introducing KardiAssure from Aegis Sciences Corporation

Aegis knows that it's more than just a test. KardiAssure provides insight at hand through the delivery of reliable and objective data that can help tailor treatment plans and improve outcomes. According to a 2017 study published in the journal Hypertensionurinalysis to determine nonadherence to prescribed antihypertensive medications is associated with improved adherence, contributing to subsequent improvements in blood pressure.

 

  • KardiAssure

    Precise

    Direct analysis of biological fluids is called the most accurate method for evaluating adherence.

  • KardiAssure

    Easy

    Non-invasive in-office collection and lab-based urinalysis – complete with integrated support team that simplifies performing test or interpreting results.

  • KardiAssure

    Comprehensive

    Capable of assessing 50+ relevant medications across 3 major CV conditions (hypertension, coronary artery disease, heart failure).

  • KardiAssure

    Supportive

    Product life-cycle support around-the-clock with a dedicated Sales, Client Services, and Clinical Scientist team.

Want to Learn More?

To learn more or begin testing, please contact our Client Services team at:

1.800.533.7052
Client.Services@aegislabs.com